Evonetix DNA IP boosted by European patent
Evonetix, a Cambridge-based synthetic biology company, has won a significant patent approval in Europe. It covers the company’s proprietary thermal control technology for DNA synthesis as well as the design and manufacture of its silicon chips.
The approval is a key step in the company’s strategy to develop a benchtop DNA synthesis platform to change how DNA is accessed, made and used.
Evonetix’s novel approach to parallel DNA synthesis is underpinned by precise, independent, control of temperature at thousands of individual synthesis sites across the surface of a silicon chip.
In contrast to conventional approaches, which use acid deprotection to control the synthesis cycle, Evonetix uses thermal control with semiconductor-based arrays.
This is said to offer greater accuracy and selectivity to deprotect sequences at the correct point to add the next nucleotide and remove mismatching sequences.
Matthew Hayes, Chief Technology Officer at Evonetix, said: “There is currently an unmet need in the synthetic biology industry for long, accurate, DNA sequences, and the ability to remove errors during assembly allows researchers to achieve longer strands of DNA, and run applications such as gene synthesis, CRISPR screening, and protein engineering.
“Securing this patent to cover our core technology adds further strength to our IP portfolio and underlines Evonetix’s position as leaders in our field. Our technology will give researchers the capabilities of service centres in their own lab, accelerating the advancement of synthetic biology and opening new possibilities in this exciting market.”